T

TCRX

Tscan Therapeutics, Inc.

1.250

-0.060-4.58%
Opening14:20 04/28 EDT

Financial Statements

Statement:

Key indicator

Income Statement

Balance Sheet

Cash Flow

Reporting Period:

Accumulated Report

FY

YoY:
FY: Financial Year Annual Report
Q: Quarter is quarterly reports. Q1, Q2, Q3 and Q4 are reports for a single quarter. Q6 and Q9 are accumulated quarterly reports, respectively contain 6 months' reports and 9 months' report.
Item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
Total Revenue

10.32M

2.82M

21.05M

13.54M

10.14M

Revenue

10.32M

2.82M

21.05M

13.54M

10.14M

Other Revenue, Total

--

--

--

--

--

Cost of Revenue, Total

--

--

--

--

--

Gross Profit

--

--

--

--

--

Operating Expense

146.14M

138.73M

114.51M

80.17M

58.78M

Selling/General/Admin.Expenses,Total

30.93M

30.29M

26.35M

20.35M

13.83M

Research & Development

110.34M

107.35M

88.15M

59.82M

44.95M

Depreciation/Amortization

2.87M

--

--

--

--

Interest Exp.(Inc.), Net-Operating, Total

--

--

--

--

--

Unusual Expense (Income)

2.00M

1.09M

--

--

--

Other Operating Expenses, Total

--

--

--

--

--

Operating Income

-135.81M

-135.91M

-93.46M

-66.64M

-48.64M

Interest Inc.(Exp.),Net-Non-Op.,Total

6.05M

8.41M

4.24M

415.00K

16.00K

Gain(Loss) on Sale of Assets

--

--

--

--

--

Other, Net

--

--

--

--

--

Net Income Before Taxes

-129.77M

-127.50M

-89.22M

-66.22M

-48.63M

Provision for Income Taxes

--

--

--

--

--

Net Income After Taxes

-129.77M

-127.50M

-89.22M

-66.22M

-48.63M

Minority Interest

--

--

--

--

--

Equity in Affiliates

--

--

--

--

--

U.S. GAAP Adjustment

--

--

--

--

--

Net Income Before Extra. Items

-129.77M

-127.50M

-89.22M

-66.22M

-48.63M

Total Extraordinary Items

--

--

--

--

--

Net Income

-129.77M

-127.50M

-89.22M

-66.22M

-48.63M

Total Adjustments to Net Income

--

--

--

--

--

Income Available to Com Excl ExtraOrd

-129.77M

-127.50M

-89.22M

-66.22M

-48.63M

Income Available to Com Incl ExtraOrd

-129.77M

-127.50M

-89.22M

-66.22M

-48.63M

Dilution Adjustment

--

--

--

--

--

Diluted Net Income

-129.77M

-127.50M

-89.22M

-66.22M

-48.63M

Diluted Weighted Average Shares

129.78M

111.99M

65.60M

24.05M

23.59M

Diluted EPS Excluding ExtraOrd Items

-0.99991

-1.13848

-1.36003

-2.75367

-2.06145

Diluted EPS including ExtraOrd Items

-0.999912

-1.138481

-1.360033

-2.75367

-2.061453

DPS – Common Stock Primary Issue

--

--

--

--

0

Diluted Normalized EPS

-0.9845

-1.12875

-1.36003

-2.75367

-2.06145